, Columnist
Celgene Shows Spending Pays
Its approach to R&D pays off in a surprisingly fast track for a new drug.
This article is for subscribers only.
Sitting on a cash pile is a popular look for big biotech. But sometimes good things come to those that spend.
A regulatory filing revealed Wednesday morning that Celgene expects to apply for FDA approval of AG-221 -- a drug it licensed from Agios that treats a tough form of blood cancer -- by the end of this year.